You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 3
  • 302 A phase IB study of indirect immunization with Oregovomab and TLR3 stimulation with hiltonol® (H) in patients with recurrent platinum resistant ovarian cancer (PROC)

Article metrics

Article menu

Download PDFPDF

E-Poster viewings
Ovarian Cancer
IGCS19-0649
302 A phase IB study of indirect immunization with Oregovomab and TLR3 stimulation with hiltonol® (H) in patients with recurrent platinum resistant ovarian cancer (PROC)
Free

 

Online download statistics by month:

Online download statistics by month: September 2019 to April 2024

AbstractFullPdf
Sep 20191407
Oct 20191204
Nov 2019603
Dec 2019603
Jan 20201802
Feb 20201005
Mar 2020606
Apr 2020800
May 20201202
Jun 20202003
Jul 20202002
Aug 2020601
Sep 20201805
Oct 20202605
Nov 20203202
Dec 20201103
Jan 2021700
Feb 20211005
Mar 2021802
Apr 2021803
May 2021402
Jun 2021104
Jul 2021004
Aug 2021002
Sep 2021004
Oct 20214018
Nov 202112013
Dec 20213201
Jan 2022601
Feb 20221000
Mar 2022804
Apr 2022202
May 20221809
Jun 20222204
Jul 20222901
Aug 20221905
Sep 20222508
Oct 20222306
Nov 2022804
Dec 20221001
Jan 2023605
Feb 2023800
Mar 20231200
Apr 2023607
May 2023200
Jun 2023201
Jul 2023802
Aug 2023201
Sep 2023201
Oct 2023601
Nov 2023802
Dec 20233900
Jan 20241400
Feb 20241402
Mar 2024901
Apr 2024501
Total6340180